Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials01:16

Clinical Trials

7.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

173
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
173
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

381
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
381

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.

Clinical pharmacology and therapeutics·2026
Same author

Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2.

Journal of comparative effectiveness research·2025
Same author

Combining Real-World and Clinical Trial Data Through Privacy-Preserving Record Linkage: Opportunities and Challenges-A Narrative Review.

Health science reports·2025
Same author

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real-World Evidence.

Clinical pharmacology and therapeutics·2025
Same author

Use of transportability methods for real-world evidence generation: a review of current applications.

Journal of comparative effectiveness research·2024
Same author

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.

Journal of comparative effectiveness research·2023
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

565

Hope is Not a Strategy: Using Robust Real-World Evidence to Make Better Clinical Development Decisions.

Nicolle M Gatto1,2, Ulka B Campbell3,4

  • 1Aetion, Inc., 5 Pennsylvania Plaza, New York, NY, 10001, USA. nicolle.gatto@aetion.com.

Therapeutic Innovation & Regulatory Science
|July 18, 2025
PubMed
Summary
This summary is machine-generated.

Systematic generation of real-world evidence (RWE) is crucial for improving clinical trial design and decision-making. This approach enhances understanding of patient populations, leading to more effective drug development.

Keywords:
Clinical developmentReal-world dataReal-world evidence

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Experiment Videos

Last Updated: Sep 8, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

565
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Area of Science:

  • Clinical Research
  • Pharmacoeconomics
  • Biostatistics

Background:

  • Clinical development faces delays and failures due to reliance on suboptimal trial designs based on expert opinion or historical data.
  • Representative, real-world point-of-care data is underutilized for understanding patient populations and indication characteristics.
  • Systematic generation of real-world evidence (RWE) is essential for informed clinical development decision-making.

Purpose of the Study:

  • To make integrated real-world evidence (RWE) generation more compelling and practicable.
  • To provide a blueprint for designing real-world studies in a phased approach aligned with clinical development investment.
  • To facilitate wider adoption of systematic RWE generation early in the development process.

Main Methods:

  • Addressing concerns raised by biopharmaceutical leaders regarding RWE generation.
  • Developing a phased approach for designing real-world studies.
  • Integrating RWE generation into the clinical development lifecycle.

Main Results:

  • Current RWE generation practices are not systematic, despite recognized value.
  • Proposed strategies aim to overcome barriers to integrated RWE generation.
  • A phased approach can align RWE studies with clinical development investment.

Conclusions:

  • Systematic RWE generation, starting early in development, is essential for evidence-based decision-making.
  • Robust RWE ensures timely data availability for sponsors, regulators, and payers.
  • Improved RWE practices can enhance clinical development efficiency and public health outcomes.